Wall Street is wondering what impact weight-loss drugs will have on consumer giants, but it may be too early to tell.
Delta Air Lines, Pepsi, Philip Morris International and Darden Restaurants are among companies facing questions about the impact of GLP-1 on their bottom lines. In the United States, only a fraction of obese people currently take a GLP-1. That figure could rise to 13% by the end of the decade, creating a $100 billion market, …
